Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Vanda Pharma ( NASDAQ:VNDA )

2 weeks ago

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. VNDA, a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.

Ticker	Sentiment	Impact
VNDA	Neutral	36 %